Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.

SOD3 induces a HIF-2α-dependent program in endothelial cells that provides a selective signal for tumor infiltration by T cells

Open access
Carmona-Rodríguez, Lorena, Martínez-Rey, Diego, Fernández-Aceñero, Maria Jesús, González-Martín, Alicia, Paz-Cabezas, Mateo, Rodríguez-Rodríguez, Noe, Pérez-Villamil, Beatriz, Sáez, Maria Eugenia, Díaz-Rubio, Eduardo, Mira, Emilia, Mañes, Santos·2020·Journal for ImmunoTherapy of Cancer

Abstract

Background: Tumor-infiltrating lymphocytes (TILs), mainly CD8+ cytotoxic T lymphocytes (CTL), are linked to immune-mediated control of human cancers and response to immunotherapy. Tumors have nonetheless developed specific mechanisms that selectively restrict T cell entry into the tumor microenvironment. The extracellular superoxide dismutase (SOD3) is an anti-oxidant enzyme usually downregulated in tumors. We hypothesize that upregulation of SOD3 in the tumor microenvironment might be a mechanism to boost T cell infiltration by normalizing the tumor-associated endothelium. Results: Here we show that SOD3 overexpression in endothelial cells increased in vitro transmigration of naïve and activated CD4+ and CD8+ T cells, but not of myeloid cells. Perivascular expression of SOD3 also specifically increased CD4+ and CD8+ effector T cell infiltration into tumors and improved the effectiveness of adoptively transferred tumor-specific CD8+ T cells. SOD3-induced enhanced transmigration in vitro and tumor infiltration in vivo were not associated to upregulation of T cell chemokines such as CXCL9 or CXCL10, nor to changes in the levels of endothelial adhesion receptors such as intercellular adhesion molecule-1 (ICAM-1) or vascular cell adhesion molecule-1 (VCAM-1). Instead, SOD3 enhanced T cell infiltration via HIF-2α-dependent induction of specific WNT ligands in endothelial cells; this led to WNT signaling pathway activation in the endothelium, FOXM1 stabilization, and transcriptional induction of laminin-α4 (LAMA4), an endothelial basement membrane component permissive for T cell infiltration. In patients with stage II colorectal cancer, SOD3 was associated with increased CD8+ TIL density and disease-free survival. SOD3 expression was also linked to a T cell–inflamed gene signature using the COAD cohort from The Cancer Genome Atlas program. Conclusion: Our findings suggest that SOD3-induced upregulation of LAMA4 in endothelial cells boosts selective tumor infiltration by T lymphocytes, thus transforming immunologically “cold” into “hot” tumors. High SOD3 levels are associated with human colon cancer infiltration by CD8+ T cells, with potential consequences for the clinical outcome of these patients. Our results also uncover a cell type–specific, distinct activity of the WNT pathway for the regulation of T cell infiltration into tumors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jitc-2019-000432

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 SOD3 selectively enhances T lymphocyte transmigration in vitro and in vivo. (A) Static adhesion of purified CD3+ T cells and CD11b+ myeloid cells to 1G11-mock and 1G11-SOD3 monolayers. Data shown as mean±SEM from a representative experiment (n=3). (B) CD3+ and CD11b+ cell transmigration through 1G11-mock or 1G11-SOD3 monolayers (n=7, 1G11-mock; n=9, 1G11-SOD3). (C) CCL19-induced transmigration of naïve CD4+ and CD8+ T cells through 1G11-mock or 1G11-SOD3 monolayers (n=11, CD4+ cells; n=6, CD8+ cells). (D) Transmigration of OVA-activated OT-II (CD4+) and OT-I (CD8+) cells through 1G11-mock or 1G11-SOD3 monolayers using CXCL10 as chemoattractant (n=5, 1G11-mock; n=6, 1G11-SOD3). (E) Scheme of the tumor model used; i.t., intratumor, i.p. intraperitoneal. (F) Growth kinetics of Ad-C-injected or Ad-SOD3-injected LLC tumors (n=4 mice/group). Arrows indicate treatment schedule with adenovirus (blue) and Doxo (green); a representative experiment is shown (n=2). (G) Kaplan-Meier survival curves for mice in (F). (H) CD3+ (green) and CD11b+ (red) cell infiltration into tumors from (F); nuclei were DAPI-stained (blue). (I) Quantification from (H) (n=8 fields; n=4 mice/group). (J) Ratio of tumor-infiltrating CD3+ and CD11b+ cells calculated from (H). (K) Ad-C-injected and Ad-SOD3-injected LLC tumor sections stained with anti-CD4+ (green) and anti-CD8+ (red) antibodies; nuclei were DAPI stained (blue). (L) Quantification from (K) (n=8 fields/condition; n=4 mice/group). (M) FoxP3+ (green) and CD8+ (red) infiltrating cells in Ad-C or Ad-SOD3 LLC tumors; nuclei (blue). (N) Quantification from (M) (n=8 fields; n=4 mice/group). (O) FoxP3+:CD8+ ratio calculated in each image from (M). Mean±SEM are shown; each data point represents an individual measurement from at least three independent experiments (B–D) or from each mouse (I–K, M, N); *p<0.05, **p<0.01, two-tailed Student’s t-test.
Figure 1 SOD3 selectively enhances T lymphocyte transmigration in vitro and in vivo. (A) Static adhesion of purified CD3+ T cells and CD11b+ myeloid cells to 1G11-mock and 1G11-SOD3 monolayers. Data shown as mean±SEM from a representative experiment (n=3). (B) CD3+ and CD11b+ cell transmigration through 1G11-mock or 1G11-SOD3 monolayers (n=7, 1G11-mock; n=9, 1G11-SOD3). (C) CCL19-induced transmigration of naïve CD4+ and CD8+ T cells through 1G11-mock or 1G11-SOD3 monolayers (n=11, CD4+ cells; n=6, CD8+ cells). (D) Transmigration of OVA-activated OT-II (CD4+) and OT-I (CD8+) cells through 1G11-mock or 1G11-SOD3 monolayers using CXCL10 as chemoattractant (n=5, 1G11-mock; n=6, 1G11-SOD3). (E) Scheme of the tumor model used; i.t., intratumor, i.p. intraperitoneal. (F) Growth kinetics of Ad-C-injected or Ad-SOD3-injected LLC tumors (n=4 mice/group). Arrows indicate treatment schedule with adenovirus (blue) and Doxo (green); a representative experiment is shown (n=2). (G) Kaplan-Meier survival curves for mice in (F). (H) CD3+ (green) and CD11b+ (red) cell infiltration into tumors from (F); nuclei were DAPI-stained (blue). (I) Quantification from (H) (n=8 fields; n=4 mice/group). (J) Ratio of tumor-infiltrating CD3+ and CD11b+ cells calculated from (H). (K) Ad-C-injected and Ad-SOD3-injected LLC tumor sections stained with anti-CD4+ (green) and anti-CD8+ (red) antibodies; nuclei were DAPI stained (blue). (L) Quantification from (K) (n=8 fields/condition; n=4 mice/group). (M) FoxP3+ (green) and CD8+ (red) infiltrating cells in Ad-C or Ad-SOD3 LLC tumors; nuclei (blue). (N) Quantification from (M) (n=8 fields; n=4 mice/group). (O) FoxP3+:CD8+ ratio calculated in each image from (M). Mean±SEM are shown; each data point represents an individual measurement from at least three independent experiments (B–D) or from each mouse (I–K, M, N); *p<0.05, **p<0.01, two-tailed Student’s t-test.CC BY-NC · PubMed Central
Figure 2 SOD3 fosters tumor-specific T lymphocyte infiltration. (A) Scheme of the tumor-specific CD8+ T cell adoptive transfer model; i.v., intravenous. (B, C) Growth kinetics of EG7-mock-induced or EG7-SOD3-induced tumors adoptively transferred with OT-I T-cells (C; arrow) or not (B) (n=7 mice/group). A representative experiment is shown (n=2). (D) Survival curves for the mice evaluated in (B, C). Curves of mice that did not receive OT-I cells are shown as dotted lines. The p values of the log-rank test for the comparisons are indicated. (E) Normalized number of OT-I cells infiltrating EG7-mock and EG7-SOD3 tumors, as determined by FACS. (F) Linear regression analyses showing the correlation between OT-I TIL and the volume for EG7-mock and EG7-SOD3 tumors. (G) SOD3 (red) and CD31 (green) staining from tumors in (A); nuclei were DAPI stained (blue). (H) Scheme of the OT-I adoptive transfer protocol in the EC-specific SOD3 transgenic (SOD3EC-Tg) mouse model. (I) Staining for SOD3 (red) and CD31 (green) in EG7 tumors; nuclei in blue (n=7/condition). (J) Growth kinetics of EG7-induced tumors implanted in control (SOD3Cre−) and SOD3EC-Tg mice. OT-I transfer is indicated (arrow) (n=9 mice/group). A representative experiment is shown (n=2). (K) Survival curves for the mice evaluated in (J). The p value of the log-rank test is indicated. (L) Normalized number of OT-I cells (×103) infiltrating EG7 tumors from mice in (J). Mean±SEM and individual values are shown; *p<0.05, two-tailed Student’s t-test.
Figure 2 SOD3 fosters tumor-specific T lymphocyte infiltration. (A) Scheme of the tumor-specific CD8+ T cell adoptive transfer model; i.v., intravenous. (B, C) Growth kinetics of EG7-mock-induced or EG7-SOD3-induced tumors adoptively transferred with OT-I T-cells (C; arrow) or not (B) (n=7 mice/group). A representative experiment is shown (n=2). (D) Survival curves for the mice evaluated in (B, C). Curves of mice that did not receive OT-I cells are shown as dotted lines. The p values of the log-rank test for the comparisons are indicated. (E) Normalized number of OT-I cells infiltrating EG7-mock and EG7-SOD3 tumors, as determined by FACS. (F) Linear regression analyses showing the correlation between OT-I TIL and the volume for EG7-mock and EG7-SOD3 tumors. (G) SOD3 (red) and CD31 (green) staining from tumors in (A); nuclei were DAPI stained (blue). (H) Scheme of the OT-I adoptive transfer protocol in the EC-specific SOD3 transgenic (SOD3EC-Tg) mouse model. (I) Staining for SOD3 (red) and CD31 (green) in EG7 tumors; nuclei in blue (n=7/condition). (J) Growth kinetics of EG7-induced tumors implanted in control (SOD3Cre−) and SOD3EC-Tg mice. OT-I transfer is indicated (arrow) (n=9 mice/group). A representative experiment is shown (n=2). (K) Survival curves for the mice evaluated in (J). The p value of the log-rank test is indicated. (L) Normalized number of OT-I cells (×103) infiltrating EG7 tumors from mice in (J). Mean±SEM and individual values are shown; *p<0.05, two-tailed Student’s t-test.CC BY-NC · PubMed Central
Figure 3 SOD3 enhances T cell transmigration through HIF-2α. (A) HIF-2α staining in 1G11-mock and 1G11-HIF-2α-overexpressing cells (n=10/condition). (B) Representative immunoblots of cells as in (A), hybridized with anti-HIF-2α and anti-β-actin antibodies. The HIF-2α:β-actin ratio (mean±SEM) is shown at bottom (n=3). (C) CCL19-induced CD4+ and CD8+ T cell transmigration through mock- and HIF-2α-overexpressing 1G11 monolayers (n=6). (D) HIF-2α staining in shNT-transfected and shHIF-2α-transfected 1G11 cells (n=12/condition). (E) Determination of HIF-2α levels in total lysates from shNT-transfected and shHIF-2α-transfected 1G11 cells. The HIF-2α:actin ratio is shown at bottom (n=3). (F) CCL19-induced transmigration of CD4+ and CD8+ T cell through 1G11-shNT and HIF-2α-silenced 1G11 monolayers (n=6). (G) Scheme of the tumor-specific CD8+ T cell adoptive transfer model used in mice with tamoxifen-inducible HIF-2α deletion in EC (HIF-2αEC-KO). (H) Normalized number of OT-I cells infiltrating EG7 tumors from mice as in (G) (n=7 mice/group from two independent experiments). (I) Tumor model used for analysis of the immune infiltrate in HIF-2αEC-KO after induction of immunogenic cell death by Doxo injection. (J) Quantification of TIL (CD3+ cells) in LLC tumors grown in control (HIF-2αf/f) and HIF-2αEC-KO mice (n=12 fields/condition; n=4 mice/group). (K) Micrographs showing CD4+ (green) and CD8+ (red) infiltrating cells in LLC tumors from (J); nuclei were DAPI stained (blue). (L) Quantification of images from (K) (n=13 fields/condition; n=4 mice/group). *p<0.05, **p<0.01, ***p<0.001, two-tailed Student’s t-test.
Figure 3 SOD3 enhances T cell transmigration through HIF-2α. (A) HIF-2α staining in 1G11-mock and 1G11-HIF-2α-overexpressing cells (n=10/condition). (B) Representative immunoblots of cells as in (A), hybridized with anti-HIF-2α and anti-β-actin antibodies. The HIF-2α:β-actin ratio (mean±SEM) is shown at bottom (n=3). (C) CCL19-induced CD4+ and CD8+ T cell transmigration through mock- and HIF-2α-overexpressing 1G11 monolayers (n=6). (D) HIF-2α staining in shNT-transfected and shHIF-2α-transfected 1G11 cells (n=12/condition). (E) Determination of HIF-2α levels in total lysates from shNT-transfected and shHIF-2α-transfected 1G11 cells. The HIF-2α:actin ratio is shown at bottom (n=3). (F) CCL19-induced transmigration of CD4+ and CD8+ T cell through 1G11-shNT and HIF-2α-silenced 1G11 monolayers (n=6). (G) Scheme of the tumor-specific CD8+ T cell adoptive transfer model used in mice with tamoxifen-inducible HIF-2α deletion in EC (HIF-2αEC-KO). (H) Normalized number of OT-I cells infiltrating EG7 tumors from mice as in (G) (n=7 mice/group from two independent experiments). (I) Tumor model used for analysis of the immune infiltrate in HIF-2αEC-KO after induction of immunogenic cell death by Doxo injection. (J) Quantification of TIL (CD3+ cells) in LLC tumors grown in control (HIF-2αf/f) and HIF-2αEC-KO mice (n=12 fields/condition; n=4 mice/group). (K) Micrographs showing CD4+ (green) and CD8+ (red) infiltrating cells in LLC tumors from (J); nuclei were DAPI stained (blue). (L) Quantification of images from (K) (n=13 fields/condition; n=4 mice/group). *p<0.05, **p<0.01, ***p<0.001, two-tailed Student’s t-test.CC BY-NC · PubMed Central
Figure 4 SOD3 induces WNT ligand transcription in endothelial cells. (A) Time-dependent accumulation of WISP2 in the supernatant of 1G11-mock and 1G11-SOD3 cells as determined by ELISA (n=3). (B) Relative WISP2 mRNA levels in 1G11-mock and 1G11-SOD3 cells (n=6). (C) Relative WISP2 mRNA levels in 1G11-mock and HIF-2α-expressing 1G11 cells (n=3). (D) Relative WISP2 mRNA levels in control (shNT) and HIF-2α-silenced 1G11 cells (n=6). (E). Scheme of the WISP2 promoter with the four HIF-2α binding sites identified. Numbers indicate positions relative to the transcription start site; arrows indicate primers used for ChIP amplification. (F) ChIP analysis of WISP2 promoter in 1G11-mock and 1G11-SOD3 cells using anti-HIF-2α antibodies. Coprecipitated DNA fragments were quantified by PCR using the primers indicated (n=3). (G, H) Relative WISP2 mRNA levels in EG7-SOD3 tumors (G; n=7 mice/group from two independent experiments), and Ad-SOD3-injected LLC tumors (H; n=4 mice/group in a representative experiment) dissected from control (HIF-2αf/f) and HIF-2αEC-KO mice from the experiments described in figure 3G, I, respectively. (I) mRNA levels of the indicated WNT ligands in 1G11-mock and 1G11-SOD3 cells. Values in 1G11-mock cells were used as reference (n=3). (J, K) Relative WNT2 and WNT2b mRNA levels in HIF-2α-overexpressing (J) or HIF-2α-silenced (K) 1G11 cells (n=3). For RT-qPCR experiments, each data point represents the mean of a technical triplicate in an independent experiment or mouse. Data shown as mean±SEM; *p<0.05, **p<0.01, ***p<0.001, two-tailed Student’s t-test.
Figure 4 SOD3 induces WNT ligand transcription in endothelial cells. (A) Time-dependent accumulation of WISP2 in the supernatant of 1G11-mock and 1G11-SOD3 cells as determined by ELISA (n=3). (B) Relative WISP2 mRNA levels in 1G11-mock and 1G11-SOD3 cells (n=6). (C) Relative WISP2 mRNA levels in 1G11-mock and HIF-2α-expressing 1G11 cells (n=3). (D) Relative WISP2 mRNA levels in control (shNT) and HIF-2α-silenced 1G11 cells (n=6). (E). Scheme of the WISP2 promoter with the four HIF-2α binding sites identified. Numbers indicate positions relative to the transcription start site; arrows indicate primers used for ChIP amplification. (F) ChIP analysis of WISP2 promoter in 1G11-mock and 1G11-SOD3 cells using anti-HIF-2α antibodies. Coprecipitated DNA fragments were quantified by PCR using the primers indicated (n=3). (G, H) Relative WISP2 mRNA levels in EG7-SOD3 tumors (G; n=7 mice/group from two independent experiments), and Ad-SOD3-injected LLC tumors (H; n=4 mice/group in a representative experiment) dissected from control (HIF-2αf/f) and HIF-2αEC-KO mice from the experiments described in figure 3G, I, respectively. (I) mRNA levels of the indicated WNT ligands in 1G11-mock and 1G11-SOD3 cells. Values in 1G11-mock cells were used as reference (n=3). (J, K) Relative WNT2 and WNT2b mRNA levels in HIF-2α-overexpressing (J) or HIF-2α-silenced (K) 1G11 cells (n=3). For RT-qPCR experiments, each data point represents the mean of a technical triplicate in an independent experiment or mouse. Data shown as mean±SEM; *p<0.05, **p<0.01, ***p<0.001, two-tailed Student’s t-test.CC BY-NC · PubMed Central
Figure 5 SOD3-induced WNT activation mediates enhanced T cell transmigration. (A) β-Catenin localization and fluorescence intensity in 1G11-mock and SOD3-expressing 1G11 cells (n=5 fields/condition). (B) Immunoblots of β-catenin (up) and β-actin (loading control) in cycloheximide-treated 1G11-mock and 1G11-SOD3 cells (n=4). (C) β-Catenin:actin densitometry ratio from (B). (D) Relative expression of the prototypic WNT-regulated genes in 1G11-mock and 1G11-SOD3 cells (n=4–7). (E) Immunoblots of FoxM1 and β-actin (loading control) in 1G11-mock and 1G11-SOD3 cells (n=4). The densitometric FoxM1:β-actin ratio is indicated (bottom). (F, G) Micrographs (F) and quantification (G) of nuclear FoxM1 fluorescence intensity in 1G11-mock and 1G11-SOD3 cells (n=7 fields/condition; >20 cells/field). Nuclei were DAPI stained (blue). (H) β-Catenin and FoxM1 levels in Vhcl-treated or XAV-939-treated 1G11-SOD3 cells. Quantification is shown at right, with β-actin as reference (n=3). (I) CCL19-induced CD4+ and CD8+ T cell transmigration through Vhcl-treated or XAV-939-treated 1G11-SOD3 monolayers (n=6). (J) β-Catenin and FoxM1 levels in 1G11-mock cells before and after stimulation with WISP2. Quantification using β-actin as reference (n=3). (K) CCL19-induced CD4+ and CD8+ T cell transmigration through 1G11 monolayers stimulated or not with WISP2 (n=5). (L) Tumor model used to test the XAV-939 effect on SOD3-induced T cell infiltration. (M) Number of OT-I cells (×103) infiltrating XAV-939-treated and Vhcl-treated EG7-SOD3 tumors (n=5 mice/group; n=2). Each data point represents an independent measurement (A, G–K, M); for (C), data are mean±SEM of four independent experiments. For (D), each data point represents the mean of a technical triplicate in an independent experiment; *p<0.05, **p<0.01, ***p<0.001, two-tailed Student’s t-test, or two-way ANOVA with Bonferroni post hoc test (C).
Figure 5 SOD3-induced WNT activation mediates enhanced T cell transmigration. (A) β-Catenin localization and fluorescence intensity in 1G11-mock and SOD3-expressing 1G11 cells (n=5 fields/condition). (B) Immunoblots of β-catenin (up) and β-actin (loading control) in cycloheximide-treated 1G11-mock and 1G11-SOD3 cells (n=4). (C) β-Catenin:actin densitometry ratio from (B). (D) Relative expression of the prototypic WNT-regulated genes in 1G11-mock and 1G11-SOD3 cells (n=4–7). (E) Immunoblots of FoxM1 and β-actin (loading control) in 1G11-mock and 1G11-SOD3 cells (n=4). The densitometric FoxM1:β-actin ratio is indicated (bottom). (F, G) Micrographs (F) and quantification (G) of nuclear FoxM1 fluorescence intensity in 1G11-mock and 1G11-SOD3 cells (n=7 fields/condition; >20 cells/field). Nuclei were DAPI stained (blue). (H) β-Catenin and FoxM1 levels in Vhcl-treated or XAV-939-treated 1G11-SOD3 cells. Quantification is shown at right, with β-actin as reference (n=3). (I) CCL19-induced CD4+ and CD8+ T cell transmigration through Vhcl-treated or XAV-939-treated 1G11-SOD3 monolayers (n=6). (J) β-Catenin and FoxM1 levels in 1G11-mock cells before and after stimulation with WISP2. Quantification using β-actin as reference (n=3). (K) CCL19-induced CD4+ and CD8+ T cell transmigration through 1G11 monolayers stimulated or not with WISP2 (n=5). (L) Tumor model used to test the XAV-939 effect on SOD3-induced T cell infiltration. (M) Number of OT-I cells (×103) infiltrating XAV-939-treated and Vhcl-treated EG7-SOD3 tumors (n=5 mice/group; n=2). Each data point represents an independent measurement (A, G–K, M); for (C), data are mean±SEM of four independent experiments. For (D), each data point represents the mean of a technical triplicate in an independent experiment; *p<0.05, **p<0.01, ***p<0.001, two-tailed Student’s t-test, or two-way ANOVA with Bonferroni post hoc test (C).CC BY-NC · PubMed Central
Figure 6 SOD3 effect on T cell transmigration parallels LAMA4 levels. (A, B) LAMA4 mRNA (A; n=10) and protein levels (green, B) in 1G11-mock and 1G11-SOD3 cells; nuclei were DAPI counterstained (blue). (C) Mean fluorescence intensity from the images in (B) (n=7 fields/condition). (D, E) LAMA4 mRNA levels in HIF-2α-overexpressing 1G11 cells (D) and HIF-2α-silenced 1G11-SOD3 (E). (F) LAMA4 mRNA levels in Vhcl-treated and XAV-939-treated 1G11-SOD3 cells (n=4). (G, H) LAMA4 staining (red) in Vhcl-treated and XAV-939-treated 1G11-SOD3 cells; nuclei (blue); quantification in (H) (n=6 fields/condition). (I) LAMA4 mRNA levels in XAV-939-treated and Vhcl-treated tumors, normalized to CD31 mRNA (n=5/group). (J) LAMA4 staining (red) in 1G11-SOD3 cells at 48 hours post-transfection with non-target (shNT) or lama4-specific (shlama4) shRNA. (K) CD4+ and CD8+ T cell transmigration through shNT-transfected or shlama4-transfected 1G11-SOD3 (n=7). (L) Transmigration of naïve T cells through 1G11 cells seeded on laminin-411 or laminin-511 (n=6). (M, N) CD31 (red), LAMA4 (green), and SOD3 (pseudo-color gray) in EG7 tumors implanted in SOD3Cre− and SOD3EC-Tg mice; quantification of the LAMA4/CD31 area in (N) (n=14 fields/condition). (O, P) CD31 (green) and LAMA4 (red) in sections from EG7-mock and EG7-SOD3 tumors; LAMA4/CD31 quantification in (P) (n=6 fields/condition). (Q, R) CD31 (red) and LAMA4 (green) staining (Q) and quantification (R; n=6 fields/condition) in Ad-C-injected and Ad-SOD3-injected LLC tumors; nuclei (blue). (S, T) Staining of CD31 (red) and LAMA4 (green) in EG7-SOD3 tumors implanted in HIF-2αf/f and HIF-2αEC-KO mice; LAMA4/CD31 area quantification in (S) (n=7/condition). (U, V) CD31 (red) and LAMA4 (green) in XAV-939-treated and Vhcl-treated tumors; quantification of the LAMA4/CD31 area in (U) (n=7/condition). Images from tumors were quantified from at least three mice/experimental condition; *p<0.05, **p<0.01, ***p<0.001, two-tailed Student’s t-test.
Figure 6 SOD3 effect on T cell transmigration parallels LAMA4 levels. (A, B) LAMA4 mRNA (A; n=10) and protein levels (green, B) in 1G11-mock and 1G11-SOD3 cells; nuclei were DAPI counterstained (blue). (C) Mean fluorescence intensity from the images in (B) (n=7 fields/condition). (D, E) LAMA4 mRNA levels in HIF-2α-overexpressing 1G11 cells (D) and HIF-2α-silenced 1G11-SOD3 (E). (F) LAMA4 mRNA levels in Vhcl-treated and XAV-939-treated 1G11-SOD3 cells (n=4). (G, H) LAMA4 staining (red) in Vhcl-treated and XAV-939-treated 1G11-SOD3 cells; nuclei (blue); quantification in (H) (n=6 fields/condition). (I) LAMA4 mRNA levels in XAV-939-treated and Vhcl-treated tumors, normalized to CD31 mRNA (n=5/group). (J) LAMA4 staining (red) in 1G11-SOD3 cells at 48 hours post-transfection with non-target (shNT) or lama4-specific (shlama4) shRNA. (K) CD4+ and CD8+ T cell transmigration through shNT-transfected or shlama4-transfected 1G11-SOD3 (n=7). (L) Transmigration of naïve T cells through 1G11 cells seeded on laminin-411 or laminin-511 (n=6). (M, N) CD31 (red), LAMA4 (green), and SOD3 (pseudo-color gray) in EG7 tumors implanted in SOD3Cre− and SOD3EC-Tg mice; quantification of the LAMA4/CD31 area in (N) (n=14 fields/condition). (O, P) CD31 (green) and LAMA4 (red) in sections from EG7-mock and EG7-SOD3 tumors; LAMA4/CD31 quantification in (P) (n=6 fields/condition). (Q, R) CD31 (red) and LAMA4 (green) staining (Q) and quantification (R; n=6 fields/condition) in Ad-C-injected and Ad-SOD3-injected LLC tumors; nuclei (blue). (S, T) Staining of CD31 (red) and LAMA4 (green) in EG7-SOD3 tumors implanted in HIF-2αf/f and HIF-2αEC-KO mice; LAMA4/CD31 area quantification in (S) (n=7/condition). (U, V) CD31 (red) and LAMA4 (green) in XAV-939-treated and Vhcl-treated tumors; quantification of the LAMA4/CD31 area in (U) (n=7/condition). Images from tumors were quantified from at least three mice/experimental condition; *p<0.05, **p<0.01, ***p<0.001, two-tailed Student’s t-test.CC BY-NC · PubMed Central
Figure 7 SOD3 associates with increased CD8+ TIL and recurrence-free survival in human colorectal cancer (CRC). (A, B) Representative images (×200; insets ×400) of tissue microarray (TMA) samples stained for SOD3, β-catenin, and LAMA4 in SOD3-positive (A) and SOD3-negative (B) tumors. Panoramic views of the TMA samples (×50) are provided in online supplementary figure S9. (C) Correlation of estimated z-scores for SOD3 and LAMA4 in images from (A) and (B). (D) Scatter plot showing individual data points and mean for LAMA4 mRNA levels in non-tumor (NT; n=13) and CRC samples (n=106) from cohort 1. (E) Correlation of SOD3 and LAMA4 mRNA levels in the CRC cohort 1. (F) Scatter plot as above for LAMA4 mRNA levels in the cohort 2 of 24 non-tumor and 90 CRC samples. (G) Correlation of SOD3 and LAMA4 mRNA levels in the CRC cohort 2. (H) Images of TMA samples stained for SOD3 and CD8, representative of SOD3-positive and negative tumors. (I, J) Correlation of estimated z-score for SOD3 and the number of CD8+ T cell in the epithelium (I) and the lamina propria (J). (K) Correlation of the LAMA4 z-score and the number of intraepithelial CD8+ TIL. (L–N) Kaplan-Meier curves for cumulative recurrence-free survival between patients with CRC based on intratumor CD8+ T cell counts (L), SOD3 positivity (M), or LAMA4 staining (N). The p value of the difference for each comparison was obtained using the log-rank test. (C, E, G, I, J, K) Pearson’s r correlation test; (D, F) *p<0.05, **p<0.01, two-tailed Student’s t-test.
Figure 7 SOD3 associates with increased CD8+ TIL and recurrence-free survival in human colorectal cancer (CRC). (A, B) Representative images (×200; insets ×400) of tissue microarray (TMA) samples stained for SOD3, β-catenin, and LAMA4 in SOD3-positive (A) and SOD3-negative (B) tumors. Panoramic views of the TMA samples (×50) are provided in online supplementary figure S9. (C) Correlation of estimated z-scores for SOD3 and LAMA4 in images from (A) and (B). (D) Scatter plot showing individual data points and mean for LAMA4 mRNA levels in non-tumor (NT; n=13) and CRC samples (n=106) from cohort 1. (E) Correlation of SOD3 and LAMA4 mRNA levels in the CRC cohort 1. (F) Scatter plot as above for LAMA4 mRNA levels in the cohort 2 of 24 non-tumor and 90 CRC samples. (G) Correlation of SOD3 and LAMA4 mRNA levels in the CRC cohort 2. (H) Images of TMA samples stained for SOD3 and CD8, representative of SOD3-positive and negative tumors. (I, J) Correlation of estimated z-score for SOD3 and the number of CD8+ T cell in the epithelium (I) and the lamina propria (J). (K) Correlation of the LAMA4 z-score and the number of intraepithelial CD8+ TIL. (L–N) Kaplan-Meier curves for cumulative recurrence-free survival between patients with CRC based on intratumor CD8+ T cell counts (L), SOD3 positivity (M), or LAMA4 staining (N). The p value of the difference for each comparison was obtained using the log-rank test. (C, E, G, I, J, K) Pearson’s r correlation test; (D, F) *p<0.05, **p<0.01, two-tailed Student’s t-test.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 58 references

Cited by

See all 56

Metadata

Authors
Carmona-Rodríguez, L., Martínez-Rey, D., Fernández-Aceñero, M. J., González-Martín, A., Paz-Cabezas, M., Rodríguez-Rodríguez, N., Pérez-Villamil, B., Sáez, M. E., Díaz-Rubio, E., Mira, E., & Mañes, S.
Affiliations
  • Department of Immunology and Oncology, Centro Nacional de Biotecnología, Madrid, Spain
  • Centro Nacional de Biotecnología (ES)
  • Surgical Pathology, Hospital Clínico Universitario San Carlos, Madrid, Spain
  • Hospital Clínico San Carlos (ES)
  • Genomics and Microarray Laboratory, Hospital Clínico Universitario San Carlos, Madrid, Spain
  • Centro Andaluz de Estudios Bioinformáticos, Sevilla, Spain
  • Clinical Oncology, Hospital Clínico Universitario San Carlos, Madrid, Spain
Corresponding author
Mañes, Santos
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2020-06
Volume
8
Issue
1
Pages
e000432
ISSN
2051-1426 (ISSN-L)
OpenAlex
W3038069830
Cited by
51
References
58
Citations by year
2026: 4 · 2025: 9 · 2024: 7 · 2023: 11 · 2022: 7 · 2021: 10 · 2020: 3
FWCI
3.25
Type
journal article
Language
en
Open access
Locations
  • Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Consejería de Sanidad, Comunidad de Madrid (B2017/BMD-3733)
  • Consejo Superior de Investigaciones Científicas (SAF2017-83732-R)
  • Ministerio de Ciencia, Innovación y Universidades (PRE2018-084023)
  • Fundación CRIS contra el cancer
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Health Sciences › Medicine › Immunology and Allergy › Cell Adhesion Molecules Research
Keywords
SOD3, extracellular superoxide dismutase, HIF-2α, tumor-infiltrating lymphocytes, CD8+ T cell infiltration, endothelial cells, Wnt signaling, FOXM1, laminin α4, tumor microenvironment, cancer immunotherapy, colorectal cancer, T cell transmigration, cold-to-hot tumor conversion
MeSH terms
Endothelial PAS Domain-Containing Protein 1, Animals, Female, Humans, Lymphocyte Activation, Mice, Inbred C57BL, Neoplasms, Superoxide Dismutase, Tumor Cells, Cultured, Signal Transduction, Lymphocytes, Tumor-Infiltrating, Mice, Knockout, CD8-Positive T-Lymphocytes, Endothelial Cells, Mice, Basic Helix-Loop-Helix Transcription Factors, Basic Helix-Loop-Helix Proteins, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: SOD3 induces a HIF-2α-dependent program in endothelial cells that provides a selective signal for tumor infiltration by T cells. https://app.cochat.ai/papers/10.1136/jitc-2019-000432
The paper
Carmona-Rodríguez, L., Martínez-Rey, D., Fernández-Aceñero, M. J., González-Martín, A., Paz-Cabezas, M., Rodríguez-Rodríguez, N., Pérez-Villamil, B., Sáez, M. E., Díaz-Rubio, E., Mira, E., & Mañes, S. (2020). SOD3 induces a HIF-2α-dependent program in endothelial cells that provides a selective signal for tumor infiltration by T cells. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2019-000432

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.